Dostarlimab Yields Sustained cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
The Southern Daily Cancers, Cremolini (UniPi): Dostarximab is effective in 70% patients with rare type rectum cancer (Adnkronos) - L'immunotherapy - can avoid many of the sequels related to the side effects of the traditional treatment path and represent the standard of care for patients with locally advanced rectum cancer who do not have metastases, but who have a fairly extensive disease, in the rectum, at local level, and deficit of the syste…
Rec News | Lontani dal mainstream
notizie.it(Adnkronos) - L'immunotherapy can avoid many of the followings related to the side effects of the traditional treatment path and represent the standard of care for patients with locally advanced rectal cancer who do not have metastases, but who have a fairly extensive disease, in the rectum, at the local level, and deficiency of the mismatch repair system (dMmr/Msi-H) -. [...] L'articolo Tumori, Cremolini (UniPi): - Dostarlimab effective in 70% …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
